Date: July 17th, 2019
Presented by: Ken Phelps, president and co-founder, Camargo
You’ve identified your product as a candidate for approval via the 505(b)(2) pathway and completed a successful pre-IND meeting. What comes next?
In part two of this webinar series on the 505(b)(2) pathway, Ken delves deeper into IND-enabling activities including CMC, toxicology and PK/PD. Discover tips for harnessing creativity to reference the right data, design and conduct the right studies and get your program to the clinic faster.